Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) ...
MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...
Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...
Taiho is parting with $400 million upfront for Araris, a spin-off from the Paul-Scherrer-Institute in Zurich, Switzerland, ...
Among 52 evaluable patients, the group who received a 2 mg/kg dose of the topoisomerase I inhibitor had an objective response rate (ORR) of 34.6%, and the group receiving a dose of 2.4 mg/kg had ...
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...
Recent findings from the RESOLVE-1 trial highlight mycophenolate mofetil's efficacy in treating diffuse cutaneous systemic ...